{"id":12314,"date":"2026-06-02T13:10:26","date_gmt":"2026-06-02T13:10:26","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=12314"},"modified":"2026-06-02T13:35:53","modified_gmt":"2026-06-02T13:35:53","slug":"alluzience-the-uks-first-liquid-toxin","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/alluzience-the-uks-first-liquid-toxin\/","title":{"rendered":"Alluzience: The UK’s First Liquid Toxin"},"content":{"rendered":"\n

The toxin market changes infrequently. Most clinics<\/mark><\/a> settle on a preferred product, a fixed dilution and a familiar injection map, and retain that routine because consistency supports reliable results and patient retention. When a genuinely different product enters the market, it warrants careful review. This article sets out the clinical and practical detail a practitioner needs to assess the newest entrant properly, including how to source it, secure a prescription and manage the patients it is offered to.<\/p>\n\n\n\n

\n
\"Aesthetic<\/figure>\n<\/figure>\n\n\n\n

What The Product Is<\/h2>\n\n\n\n

The product discussed here, Alluzience, is the first ready-to-use, pre-mixed liquid botulinum toxin<\/mark><\/a> type A licensed in Europe, developed by Ipsen and brought to market by Galderma. Its defining characteristic is the presentation. It is supplied as a liquid, in a vial, ready to inject, which removes reconstitution from the workflow.<\/p>\n\n\n\n

Patients often search for Alluzience Botox when researching the treatment<\/mark><\/a>, though the product is not Botox at all; Botox is Allergan’s brand of onabotulinumtoxinA, whereas this is a separate type A toxin. For comparison, the other toxins used in the UK, including Azzalure, Bocouture<\/mark><\/a>, Botox, Dysport<\/mark><\/a> and Letybo<\/mark><\/a>, are supplied as freeze-dried powders that require reconstitution before treatment. The liquid formulation removes that step. As a prescription-only medicine it still has to be obtained through a pharmacy against a valid prescription, which practitioners can do through the Faces Pharmacy<\/mark><\/a>, covered in more detail later in this article.<\/p>\n\n\n\n

You can also read more information about toxins in this related blog: Top 5 Toxin Brands in the UK<\/mark><\/a><\/p>\n\n\n\n

Formulation<\/h2>\n\n\n\n

The formulation is the most clinically significant aspect of any anti-wrinkle injection<\/mark><\/a> and the area most often overlooked.<\/p>\n\n\n\n

Active substance and unit system<\/h3>\n\n\n\n

The active substance is botulinum toxin type A (abobotulinumtoxinA), supplied at a concentration of 200 Speywood units per ml. Each vial contains 125 Speywood units in 0.625 ml of solution.<\/p>\n\n\n\n

The central point is that Speywood units are not interchangeable with the units of other toxins. A unit of this product is not equivalent to a unit of Botox<\/mark><\/a> or Bocouture. Practitioners who already work with Azzalure or Dysport are accustomed to Speywood units, so the dosing framework transfers directly. Those moving from an onabotulinumtoxinA product cannot apply a 1:1 conversion. This is the most common dosing error made when injectors transition between toxin families.<\/p>\n\n\n\n

Excipients<\/h3>\n\n\n\n

The remaining ingredients are L-histidine, sucrose, sodium chloride, polysorbate 80, hydrochloric acid (for pH adjustment) and water for injection.<\/p>\n\n\n\n

Of particular note is the absence of human serum albumin and lactose. The product is manufactured using production technology that removes the need for these stabilisers, making it free from human and animal-derived proteins. This is relevant for patients who ask about animal-derived content, those with specific dietary or religious considerations, and those concerned about blood-derived stabilisers. It is a point worth recording on the consent form<\/mark><\/a> during the consultation.<\/p>\n\n\n\n

Mechanism of action<\/h3>\n\n\n\n

The toxin acts in the same way as other type A products. At the neuromuscular junction it blocks the release of acetylcholine, preventing the targeted muscle from contracting. The visible smoothing effect is the result of this temporary chemical denervation. The underlying biology is unchanged; the difference lies in the formulation and presentation.<\/p>\n\n\n\n

Onset and Duration<\/h2>\n\n\n\n

Onset and duration are the characteristics patients value most, and the areas where the product differentiates itself.<\/p>\n\n\n\n

In the pooled pivotal trials of 372 patients, more than half reported an effect within two to three days, and approximately 23% reported an effect within the first 24 hours. This rapid onset is clinically useful, allowing practitioners to advise first-time patients that softening of movement may be visible within a couple of days.<\/p>\n\n\n\n

An effect was demonstrated for up to six months in trials. Responder rates were highest in the first one to two months and declined over time, so six months represents the upper limit rather than a typical outcome. A realistic expectation to set with patients is a reliable three to four months, with the potential for longer in some cases. Recording this expectation clearly within the consultation and consent record supports patient satisfaction at the review appointment.<\/p>\n\n\n\n

Alluzience Dosage and Injection Technique<\/h2>\n\n\n\n

The licensed indication is moderate to severe glabellar lines (with crow’s feet also within scope in the UK product information) in adults under 65.<\/p>\n\n\n\n

For the glabellar complex, the recommended dose is 50 Speywood units in total, distributed across five points: two into each corrugator and one into the procerus, at 10 units per point. For lateral canthal lines, the consensus and product guidance specify 30 units per side across three points. Practitioners already injecting Azzalure<\/mark><\/a> will recognise this pattern, as it is essentially identical.<\/p>\n\n\n\n

Practical considerations include the following:<\/p>\n\n\n\n